RhIGF (Increlex) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00764699 (ClinicalTrials.gov) | October 2008 | 1/10/2008 | Effect of Increlex® on Children With Crohn Disease | Effect of Increlex® on Children With Crohn Disease | Crohn Disease | Drug: rhIGF (Increlex) | Nationwide Children's Hospital | Tercica | Terminated | 5 Years | 15 Years | All | 3 | Phase 2/Phase 3 | United States |